Editorial
Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution
Translational Lung Cancer Research
2018;
7
(Suppl 2)
:S91-S94
.
(23 April 2018)
Companion and complementary diagnostics for first-line immune checkpoint inhibitor treatment in non-small cell lung cancer
Translational Lung Cancer Research
2018;
7
(Suppl 2)
:S95-S99
.
(23 April 2018)
Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken option
Translational Lung Cancer Research
2018;
7
(Suppl 2)
:S100-S102
.
(23 April 2018)
Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start
Translational Lung Cancer Research
2018;
7
(Suppl 2)
:S103-S106
.
(23 April 2018)
Stage III non-small cell lung cancer: escalation matters, but how?
Translational Lung Cancer Research
2018;
7
(Suppl 2)
:S107-S110
.
(23 April 2018)
A promising result of locoregional tumor control with biologically adaptive radiotherapy in patients with locally advanced non-smallcell lung cancer
Translational Lung Cancer Research
2018;
7
(Suppl 2)
:S111-S113
.
(23 April 2018)
Patient selection for future lung cancer computed tomography screening programmes: lessons learnt post National Lung Cancer Screening Trial
Translational Lung Cancer Research
2018;
7
(Suppl 2)
:S114-S116
.
(23 April 2018)
Repurposing established cyclic adenosine monophosphate reducing agents for the prevention and therapy of epidermal growth factor receptor inhibitor resistance in non-small cell lung cancer
Translational Lung Cancer Research
2018;
7
(Suppl 2)
:S117-S122
.
(23 April 2018)
Stressing the need to overcome EGFR tyrosine kinase inhibitor resistance
Translational Lung Cancer Research
2018;
7
(Suppl 2)
:S123-S126
.
(23 April 2018)
First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC
Translational Lung Cancer Research
2018;
7
(Suppl 2)
:S127-S130
.
(23 April 2018)
No room for statins in the quest for survival benefits in small cell lung cancer
Translational Lung Cancer Research
2018;
7
(Suppl 2)
:S131-S133
.
(23 April 2018)
The evolving first-line treatment of advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations
Translational Lung Cancer Research
2018;
7
(Suppl 2)
:S134-S137
.
(23 April 2018)
Patient-related outcomes with the use of checkpoint inhibitors for the treatment of metastatic non-small cell lung cancer
Translational Lung Cancer Research
2018;
7
(Suppl 2)
:S138-S141
.
(23 April 2018)
EGFR targeted therapy for lung cancer: are we almost there?
Translational Lung Cancer Research
2018;
7
(Suppl 2)
:S142-S145
.
(23 April 2018)
Precision radiotherapy for patients with locally advanced non-small cell lung cancer in the era of immunotherapy and precision medicine
Translational Lung Cancer Research
2018;
7
(Suppl 2)
:S146-S148
.
(23 April 2018)
Quality of life for non-small cell lung cancer patients in the age of immunotherapy
Translational Lung Cancer Research
2018;
7
(Suppl 2)
:S149-S152
.
(23 April 2018)
Durvalumab for non-resectable stage IIIB non-small cell lung cancer—a small step or a big leap?
Translational Lung Cancer Research
2018;
7
(Suppl 2)
:S153-S157
.
(23 April 2018)
Editorial commentary: meeting a paramount challenge
Translational Lung Cancer Research
2018;
7
(Suppl 2)
:S158-S159
.
(23 April 2018)
Can we use interleukin-1β blockade for lung cancer treatment?
Translational Lung Cancer Research
2018;
7
(Suppl 2)
:S160-S164
.
(23 April 2018)
Osimertinib in untreated epidermal growth factor receptor (EGFR)- mutated advanced non-small cell lung cancer
Translational Lung Cancer Research
2018;
7
(Suppl 2)
:S165-S170
.
(23 April 2018)
Post-operative radiation therapy in locally advanced non-small cell lung cancer and the impact of sequential versus concurrent chemotherapy
Translational Lung Cancer Research
2018;
7
(Suppl 2)
:S171-S175
.
(23 April 2018)
The continued EGFR-TKI with cytotoxic chemotherapy at progression—poison or medicine?
Translational Lung Cancer Research
2018;
7
(Suppl 2)
:S176-S178
.
(23 April 2018)
Adjuvant bevacizumab for resected non-small cell lung cancer: the end of an era?
Translational Lung Cancer Research
2018;
7
(Suppl 2)
:S179-S182
.
(23 April 2018)
Disclosure:
The supplement was commissioned by the editorial office, Translational Lung Cancer Research without any sponsorship or funding.
